Patents by Inventor Elihu H. Estey

Elihu H. Estey has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Using plasma proteomic pattern for diagnosis, classification, prediction of response to therapy and clinical behavior, stratification of therapy, and monitoring disease in hematologic malignancies
    Patent number: 8563323
    Abstract: The present invention demonstrates that the diagnosis and prediction of clinical behavior in patients with hematologic malignancies, such as leukemia, can be accomplished by analysis of proteins present in a plasma sample. Thus, in particular embodiments the present invention uses plasma to create a diagnostic or prognostic protein profile of a hematologic malignancy comprising collecting plasma samples from a population of patients with hematologic malignancies; generating protein spectra from the plasma samples with or without fractionation; comparing the protein spectra with clinical data; and identifying protein markers in the plasma samples that correlate with the clinical data. Protein markers identified by this approach can then be used to create a protein profile that can be used to diagnose the hematologic malignancy or determine the prognosis of the hematologic malignancy. Potentially these specific proteins can be identified and targeted in the therapy of these malignancies.
    Type: Grant
    Filed: December 14, 2011
    Date of Patent: October 22, 2013
    Assignee: Board of Regents, The University of Texas System
    Inventors: Maher Albitar, Elihu H. Estey, Hagop M. Kantarjian, Francis J. Giles, Michael J. Keating
  • Using Plasma Proteomic Pattern For Diagnosis, Classification, Prediction Of Response To Therapy And Clinical Behavior, Stratification Of Therapy, And Monitoring Disease In Hematologic Malignancies
    Publication number: 20120145891
    Abstract: The present invention demonstrates that the diagnosis and prediction of clinical behavior in patients with hematologic malignancies, such as leukemia, can be accomplished by analysis of proteins present in a plasma sample. Thus, in particular embodiments the present invention uses plasma to create a diagnostic or prognostic protein profile of a hematologic malignancy comprising collecting plasma samples from a population of patients with hematologic malignancies; generating protein spectra from the plasma samples with or without fractionation; comparing the protein spectra with clinical data; and identifying protein markers in the plasma samples that correlate with the clinical data. Protein markers identified by this approach can then be used to create a protein profile that can be used to diagnose the hematologic malignancy or determine the prognosis of the hematologic malignancy. Potentially these specific proteins can be identified and targeted in the therapy of these malignancies.
    Type: Application
    Filed: December 14, 2011
    Publication date: June 14, 2012
    Inventors: Maher Albitar, Elihu H. Estey, Hagop M. Kantarjian, Francis J. Giles, Michael J. Keating
  • Using plasma proteomic pattern for diagnosis, classification, prediction of response to therapy and clinical behavior, stratification of therapy, and monitoring disease in hematologic malignancies
    Patent number: 8097468
    Abstract: The present invention demonstrates that the diagnosis and prediction of clinical behavior in patients with hematologic malignancies, such as leukemia, can be accomplished by analysis of proteins present in a plasma sample. Thus, in particular embodiments the present invention uses plasma to create a diagnostic or prognostic protein profile of a hematologic malignancy comprising collecting plasma samples from a population of patients with hematologic malignancies; generating protein spectra from the plasma samples with or without fractionation; comparing the protein spectra with clinical data; and identifying protein markers in the plasma samples that correlate with the clinical data. Protein markers identified by this approach can then be used to create a protein profile that can be used to diagnose the hematologic malignancy or determine the prognosis of the hematologic malignancy. Potentially these specific proteins can be identified and targeted in the therapy of these malignancies.
    Type: Grant
    Filed: October 21, 2009
    Date of Patent: January 17, 2012
    Assignee: Board of Regents, The University of Texas System
    Inventors: Maher Albitar, Elihu H. Estey, Hagop M. Kantarjian, Francis J. Giles, Michael J. Keating
  • Using Plasma Proteomic Pattern For Diagnosis, Classification, Prediction of Response to Therapy and Clinical Behavior, Stratification of Therapy, and Monitoring Disease in Hematologic Malignancies
    Publication number: 20100063747
    Abstract: The present invention demonstrates that the diagnosis and prediction of clinical behavior in patients with hematologic malignancies, such as leukemia, can be accomplished by analysis of proteins present in a plasma sample. Thus, in particular embodiments the present invention uses plasma to create a diagnostic or prognostic protein profile of a hematologic malignancy comprising collecting plasma samples from a population of patients with hematologic malignancies; generating protein spectra from the plasma samples with or without fractionation; comparing the protein spectra with clinical data; and identifying protein markers in the plasma samples that correlate with the clinical data. Protein markers identified by this approach can then be used to create a protein profile that can be used to diagnose the hematologic malignancy or determine the prognosis of the hematologic malignancy. Potentially these specific proteins can be identified and targeted in the therapy of these malignancies.
    Type: Application
    Filed: October 21, 2009
    Publication date: March 11, 2010
    Inventors: Maher Albitar, Elihu H. Estey, Hagop M. Kantarjian, Francis J. Giles, Michael J. Keating
  • Using plasma proteomic pattern for diagnosis, classification, prediction of response to therapy and clinical behavior, stratification of therapy, and monitoring disease in hematologic malignancies
    Patent number: 7622306
    Abstract: The present invention demonstrates that the diagnosis and prediction of clinical behavior in patients with hematologic malignancies, such as leukemia, can be accomplished by analysis of proteins present in a plasma sample. Thus, in particular embodiments the present invention uses plasma to create a diagnostic or prognostic protein profile of a hematologic malignancy comprising collecting plasma samples from a population of patients with hematologic malignancies; generating protein spectra from the plasma samples with or without fractionation; comparing the protein spectra with clinical data; and identifying protein markers in the plasma samples that correlate with the clinical data. Protein markers identified by this approach can then be used to create a protein profile that can be used to diagnose the hematologic malignancy or determine the prognosis of the hematologic malignancy. Potentially these specific proteins can be identified and targeted in the therapy of these malignancies.
    Type: Grant
    Filed: April 20, 2005
    Date of Patent: November 24, 2009
    Assignee: Board of Regents, The University of Texas System
    Inventors: Maher Albitar, Elihu H. Estey, Hagop M. Kantarjian, Francis J. Giles, Michael J. Keating
  • Method of cancer treatment
    Patent number: 7204996
    Abstract: This invention comprises a method of treating a subject having relapsed or refractory cancer such as leukemia with liposomal annamycin including the steps of (a) evaluating the subject to determine if the subject has relapsed or refractory cancer; (b) administering a high-dose amount of liposomal-annamycin for at least 3 days in a 7 day period. First line cancer therapy with particular reference to leukemia is both contemplated and useful.
    Type: Grant
    Filed: June 10, 2005
    Date of Patent: April 17, 2007
    Assignee: Board of Regents, The University of Texas System
    Inventors: Michael Andreeff, Elihu H Estey
  • Method of cancer treatment
    Patent number: 6929802
    Abstract: This invention comprises a method of treating a subject having relapsed or refractory cancer such as leukemia with liposomal annamycin including the steps of (a) evaluating the subject to determine if the subject has relapsed or refractory cancer; (b) administering a high-dose amount of liposomal-annamycin for at least 3 days in a 7 day period. First line cancer therapy with particular reference to leukemia is both contemplated and useful.
    Type: Grant
    Filed: April 18, 2003
    Date of Patent: August 16, 2005
    Assignee: Board of Regents, The University of Texas System
    Inventors: Michael Andreeff, Elihu H. Estey
  • Method of cancer treatment
    Publication number: 20040057989
    Abstract: This invention comprises a method of treating a subject having relapsed or refractory cancer such as leukemia with liposomal annamycin including the steps of
    Type: Application
    Filed: April 18, 2003
    Publication date: March 25, 2004
    Applicant: Board of Regents, The University of Texas System
    Inventors: Michael Andreeff, Elihu H. Estey